Construction and phenotypic analysis of p2rx2 knockout zebrafish lines.
10.11817/j.issn.1672-7347.2025.240659
- Author:
Yong ZHANG
1
,
2
;
Qingying SHI
3
;
Hao XIE
3
;
Binling XIE
3
;
Lihua LI
4
;
Weijing WU
1
;
Huaping XIE
3
;
Zi'an XIAO
1
;
Dinghua XIE
1
;
Ruosha LAI
1
,
5
Author Information
1. Department of Otolaryngology-Head and Neck Surgery, Second Xiangya Hospital, Central South University, Changsha
2. 765415941@qq.com.
3. Hunan Provincial Key Laboratory of Animal Intestinal Function and Regulation, Changsha
4. Department of Otolaryngology-Head and Neck Surgery, Second Affiliated Hospital, Nanchang University, Nanchang 330006, China.
5. lairuosha@csu.edu.cn.
- Publication Type:Journal Article
- Keywords:
CRISPR/Cas9 system;
hair cell;
p2rx2;
purinergic receptor P2X2;
zebrafish
- MeSH:
Animals;
Zebrafish/genetics*;
Receptors, Purinergic P2X2/deficiency*;
CRISPR-Cas Systems/genetics*;
Gene Knockout Techniques;
Phenotype;
Zebrafish Proteins/genetics*;
Disease Models, Animal
- From:
Journal of Central South University(Medical Sciences)
2025;50(6):919-930
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:The purinergic receptor P2X2 (P2RX2) encodes an ATP-gated ion channel permeable to Na+, K+, and especially Ca²⁺. Loss-of-function mutations in P2RX2 are known to cause autosomal dominant nonsyndromic deafness 41 (DFNA41), which manifests as high-frequency hearing loss, accelerated presbycusis, and increased susceptibility to noise-induced damage. Zebrafish, owing to their small size, rapid development, high fecundity, transparent embryos, and high gene conservation with humans, provide an ideal model for studying human diseases and developmental mechanisms. This study aims to generate a p2rx2 knockout zebrafish model using CRISPR/Cas9 gene editing system to investigate the effect of p2rx2 deficiency on the auditory system, providing a basis for understanding P2RX2-related hearing loss and developing gene therapy strategies.
METHODS:Two CRISPR targets (sgRNA1 and sgRNA2) spaced 47 bp apart were designed within the zebrafish p2rx2 gene. Synthesized sgRNAs and Cas9 protein were microinjected into single-cell stage Tübingen (TU)-strain zebrafish embryos. PCR and gel electrophoresis verified editing efficiency at 36 hours post-fertilization (hpf). Surviving embryos were raised to adulthood (F0), tail-clipped, genotyped, and screened for positive mosaics. F1 heterozygotes were generated by outcrossing, and F2 homozygous mutants were obtained by intercrossing. Polymerase chain reaction (PCR) combined with sequencing verified mutation type and heritability. At 5 days post-fertilization (dpf), YO-PRO-1 staining was used to examine hair cell morphology and count in lateral line neuromasts and the otolith region. Auditory evoked potential (AEP) thresholds at 600, 800, 1 000, and 2 000 Hz were measured in nine 4-month-old wild type and mutant zebrafish per group.
RESULTS:A stable p2rx2 knockout zebrafish line was successfully established. Sequencing revealed a 66 bp insertion at the first target site introducing a premature stop codon (TAA), leading to early termination of protein translation and loss of function. Embryos developed normally with no gross malformations. At 5 dpf, mutants exhibited significantly reduced hair cell density in the otolith region compared with wild type, although lateral line neuromasts were unaffected. AEP testing showed significantly elevated auditory thresholds at all 4 frequencies in homozygous mutants compared with wild type (all P<0.001), indicating reduced hearing sensitivity.
CONCLUSIONS:We successfully generated a p2rx2 loss-of-function zebrafish model using CRISPR/Cas9 technology. p2rx2 deficiency caused hair cell defects in the otolith region and increased auditory thresholds across frequencies, indicating its key role in maintaining zebrafish auditory hair cell function and hearing perception. The phenotype's restriction to the otolith region suggests tissue-specific roles of p2rx2 in sensory organs. This model provides a valuable tool for elucidating the molecular mechanisms of P2RX2-related hearing loss and for screening otoprotective drugs and developing gene therapies.
